Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy.
It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.


Product Name Fulvestrant
CAS Number 129453-61-8
Therapeutic Class Antineoplastic Agents; Hormonal Estrogen Antagonists
Dosage Form Parenteral injection for IM use only, 50 mg/mL
Availability Commercial
Regulatory Status USDMF, CEP